| 0.1735 -0.028 (-13.85%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Teligent, Inc., formerly known as Igi Laboratories Inc, functions as a specialized generic pharmaceutical enterprise. Operating under its own brand, the company markets and distributes generic injectable medications throughout the United States and Canada. As of December 31, 2018, its U.S. product offerings encompassed 35 generic topical drugs and four branded generic pharmaceutical items. Beyond its proprietary products, Teligent also provides development, formulation, and manufacturing expertise to the pharmaceutical, over-the-counter (OTC), and cosmetic sectors. The company's strategic focus involves the creation, production, and promotion of its own range of generic pharmaceutical products, available in various delivery forms such as topical, injectable, complex, and ophthalmic preparations. Concurrently, it manages its business segment dedicated to contract manufacturing and formulation services. By the close of 2018, Teligent's future product pipeline included 20 Abbreviated New Drug Applications (ANDAs) that had been filed with the U.S. Food and Drug Administration (FDA) for additional pharmaceutical offerings.
Mon, 28 Feb 2022
Teligent seeks to convert bankruptcy to Chapter 7 amid impasse with creditors - The Business Journals
Sun, 26 Mar 2017
3 Stocks That Could Make You Rich - The Motley Fool
Tue, 11 Oct 2016
Teligent, Inc. Announces The Opening Of A Product Development Laboratory In Estonia - PR Newswire
Fri, 24 Jun 2016
Teligent Completes Acquisition of Alveda Pharmaceuticals' Assets - SEC.gov
Thu, 22 Oct 2015
IGI Laboratories, Inc. Announces Name Change To Teligent, Inc. - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|